Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic umbilical cord-derived CD34- cells, unexpanded/dorocubicel - Cordex Biologics

Next Previous
Drug Profile

Allogeneic umbilical cord-derived CD34- cells, unexpanded/dorocubicel - Cordex Biologics

Alternative Names: ECT 001; ECT-001-CB; UM 171 cell therapy - Cordex Biologics; UM171- expanded cord blood transplantation - Cordex Biologics; Zemcelpro

Latest Information Update: 19 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ExCellThera
  • Developer Cordex Biologics; ExCellThera
  • Class Antineoplastics; Haematopoietic stem cells therapies; Immunotherapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies; Graft-versus-host disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Haematological malignancies
  • Phase I/II Multiple myeloma

Most Recent Events

  • 16 Feb 2026 Dorocubicel receives NUB status 1 in Germany
  • 31 Dec 2025 ExCellThera completes a phase I/II clinical trials in Haematological malignancies (In infants, In adolescents, In children, In adults) in USA (IV, Infusion) (NCT04990323)
  • 06 Oct 2025 Ciusss de L'Est de l'Île de Montréal and ExcellThera initiates phase I/II clinical trials in Haematological malignancies in Canada (IV, Infusion) (NCT07301866)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top